Navigation Links
Quark Pharmaceuticals Presents at Asia TIDES Conference
Date:3/9/2009

products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.        The Ruth Group (investors / media)
    Juliana Friedman                   Sara Ephraim / Janine McCargo
    +972 89 30 5111                    (646) 536-7004 / 7033
    jfriedman@quarkpharma.com          sephraim@theruthgroup.com
                                       jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 According to Millennium Research ... market intelligence, increased use of safety devices for ... be a key driver of the enteral feeding ... MRG,s new US and European Markets for ... the giving set segment will experience the greatest ...
(Date:12/14/2009)... 14 Mylan Inc. (Nasdaq: MYL ... added to the NASDAQ-100 Index Dec. 21. Mylan,s ... PowerShares QQQ. ,, Mylan Chairman and CEO Robert ... join NASDAQ,s most widely followed index of leading ... for Mylan and reflects the rapid growth and ...
(Date:12/14/2009)... -- Pf enex Inc. announced today ... an affiliate, an exclusive worldwide license to Pf ... technology for the production of specific proteins ... vaccine candidate. ,, Under the terms of the ... $52 million in upfront and milestone payments as well ...
Breaking Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Mylan Added to NASDAQ-100 Index 2Altcharge com Announces New Services in the Processing Industry 61099 1Altcharge com Announces New Services in the Processing Industry 61099 2Particle Sciences Acquires Additional Space for Operations 14790 1Particle Sciences Acquires Additional Space for Operations 14790 2Amedica Announces New Product Offering 14788 1Amedica Announces New Product Offering 14788 2
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported today ... that its EnviroTru(R),disinfectant has been assigned a commodity ... the State of Florida. The Company reported,that its ... http://www.aworldofgreen.com ),worked with the DMS to have ...
... An overwhelming number of,Americans with memory concerns ... despite visits within the past six months, according ... in the Alzheimer,s Foundation of,America (AFA) National Memory ... results at a poster session at the Alzheimer,s,Association,s ...
Other Medicine Technology:Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 2Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 3
(Date:12/15/2009)... Oakworks ® Inc. America,s premier manufacturer of Spa, Massage, and ... the development of an adjustable breast comfort system to ease ... ... New Freedom, Pennsylvania (PRWEB) December 15, ... massage, and medical equipment, today announced the launch of the ...
(Date:12/15/2009)... and Telangiectasia , ... (PRWEB) December 10, 2009 -- Millions of men ... – those unsightly clusters of red, blue or purple veins that spider-web ... populations like the US, it’s been estimated that 25-30% of women and ... , ,Although the Veinwave has been available for over 8 ...
(Date:12/15/2009)... SAN DIEGO, Dec. 15 "The entire San ... mourns the passing of Sol Price on December 14, ... standards of integrity, loyalty and ethics in his business, ... and thoughtful humanitarian who truly understood the responsibility of ... and his legacy will live on through his countless ...
(Date:12/15/2009)... Westchester, Ill. A study in the Dec. ... Sleep Medicine indicates that significant associations exist ... gastrointestinal regurgitation and headaches in young school-aged children. ... that parent-reported insomnia was 3.3 times more likely ... more likely in children with headaches. Nineteen ...
(Date:12/14/2009)... Unmarried Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, ... Nearly all unmarried young adults ages 18-29 ... of men and 86% of women) and say that ... right now (86% of men and 88% of women), ... to Prevent Teen and Unplanned Pregnancy. Even so: ...
Breaking Medicine News(10 mins):Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3
... why some nonsmokers contract the disease, study says , , TUESDAY, ... the risk of lung cancer, even in nonsmokers, researchers report. ... gene double someones risk of developing lung cancer, regardless of ... why some nonsmokers develop the disease, said study author Dr. ...
... SMTS ) announced today that it has received ... to expand the labeling for its,INVOS Cerebral/Somatic Oximeter System., ... support our ongoing efforts,in the pediatric and neonatal ICU ... and CEO. "First, the 510(k) expands,the indication for use ...
... Academy of General,Dentistry (AGD) applauds the recent introduction ... Sen. Benjamin Cardin (D-MD) and Sen. Susan,Collins (R-ME). ... a,multi-faceted approach to oral health care through the ... assess existing federal oral health,programs and recommend improvements., ...
... Md., and Deerfield, Ill., May 27, 2008 Sucampo ... Inc. today announced that AMITIZA (lubiprostone) 8 mcg capsules ... U.S. for the treatment of Irritable Bowel Syndrome with ... AMITIZA 24 mcg capsules have been available by prescription ...
... guest editorial published in the June issue of the ... National Institute of Dental and Craniofacial Research (NIDCR) in ... United States. Authored by NIDCR Director Lawrence A. Tabak ... oral health research and the traditional research community can ...
... The,Biomedical Excellence for Safer Transfusion (BEST) Collaborative ... and medical,implications of several recent papers purporting to ... Cells leads to greater risk. The organization,will highlight ... and Human,Services (HHS) meeting of the Advisory Committee ...
Other Medicine News:Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3Health News:Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling 2Health News:AGD Applauds Sen. Cardin Oral Health Initiative Bill; Urges All Senators to Co-Sponsor Measure 2Health News:AMITIZA 8 mcg now available to treat irritable bowel syndrome 2Health News:AMITIZA 8 mcg now available to treat irritable bowel syndrome 3Health News:NIDCR strategies for future scientific success 2Health News:International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk 2Health News:International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk 3
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... and specific second-generation peptide-based test, DIASTAT Anti-CCP* ... of autoantibodies against the cyclic citrullinated peptide ... serum or plasma. Enabling early and accurate ... an additional tool in the diagnosis and ...
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Hemagglutination slide test for the qualitative detection and quantitative determination of antibodies to streptococcal extracellular antigens in serum, plasma, or whole blood....
Medicine Products: